Showing results (21-30 of 66) with videos related to
Sort By:
Pageof 7
Clinical Advances in Hematology & Oncology : H&O|August 17, 2012
A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancerJohanna C Bendell, Anthony Meluch, James Peyton, et al.BMC Pulmonary Medicine|May 14, 2026
Real-world treatment and healthcare resource utilization patterns among patients with advanced non-small cell lung cancer treated with amivantamab: a retrospective study using insurance claims dataDavid Waterhouse, Iris Lin, Laura Morrison, et al.Brachytherapy|July 23, 2013
Validation of a radiobiological model for low-dose-rate prostate boost focal therapy treatment planningAnnette Haworth, Scott Williams, Hayley Reynolds, et al.Future Oncology (London, England)|July 27, 2023
Durvalumab real-world treatment patterns and outcomes in patients with stage III non-small-cell lung cancer treated in a US community settingDavid Waterhouse, Candice Yong, Andrew Frankart, et al.American Journal of Hematology|July 9, 2016
A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemiaIan W Flinn, Amy S Ruppert, William Harwin, et al.Physical and Engineering Sciences in Medicine|November 15, 2021
Report of the ACPSEM radiation oncology medical physics workforce modelling project task groupScott Crowe, Trent Aland, Lotte Fog, et al.Journal of Health Economics and Outcomes Research|September 2, 2025
Healthcare Resource Use, Healthcare Costs, and Unmet Needs Among Patients Treated for EGFR-Mutated Advanced or Metastatic Non-small Cell Lung CancerDavid Waterhouse, Iris Li, Laura Morrison, et al.Future Oncology (London, England)|April 14, 2021
Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapyDavid Stenehjem, Solomon Lubinga, Keith A Betts, et al.Cancer Investigation|August 2, 2017
First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC)David R Spigel, Tarek M Mekhail, David Waterhouse, et al.Lung Cancer (Amsterdam, Netherlands)|April 24, 2021
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancerDavid Waterhouse, Jenny Lam, Keith A Betts, et al.Pageof 7